Isoforms of the class II transactivator protein

International Immunology

Volumn 14, Issue 8, 2002, Pages 839-848

  Barbieri, Giovanna ^a,d   Deffrennes, Virginie ^a   Prod'homme, Thomas ^a   Vedrenne, Jocelyn ^a   Baton, Fabrice ^a   Cortes, Claudio ^c   Fischer, Alain ^b   Bono, Maria Rosa ^c   Lisowska Grospierre, Barbara ^b   Charron, Dominique ^a   Alcaïde Loridan, Catherine ^a,e  

^a SAINT LOUIS HOSPITAL   (France)

^b HÔPITAL NECKER ENFANTS MALADES   (France)

^c UNIVERSITY OF CHILE   (Chile)

^d CNR   (Italy)

^e INSERM   (France)

Author keywords

Gene regulation; HLA; Melanoma; MHC; Promoter; Transcription

Indexed keywords

CYTOKINE; GAMMA INTERFERON; ISOPROTEIN; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 2; TRANSACTIVATOR PROTEIN; HLA D ANTIGEN; MESSENGER RNA; MHC CLASS II TRANSACTIVATOR PROTEIN; NUCLEAR PROTEIN; RECOMBINANT GAMMA INTERFERON; RECOMBINANT PROTEIN;

ACCURACY; ARTICLE; B LYMPHOCYTE; CANCER CELL CULTURE; CELL NUCLEUS; CELL TYPE; CONTROLLED STUDY; FIBROBLAST; FIBROBLAST CULTURE; GENE TRANSLOCATION; HUMAN; HUMAN CELL; IMMUNOMODULATION; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN LOCALIZATION; START CODON; TRANSLATION INITIATION; ACTIVE TRANSPORT; AMINO ACID SEQUENCE; CELL CULTURE; CELL LINE; DRUG EFFECT; GENE; GENE EXPRESSION; GENETIC TRANSFECTION; GENETICS; HELA CELL; KINETICS; METABOLISM; MOLECULAR GENETICS; NUCLEOTIDE SEQUENCE; SITE DIRECTED MUTAGENESIS;

ACTIVE TRANSPORT, CELL NUCLEUS; AMINO ACID SEQUENCE; BASE SEQUENCE; CELL LINE; GENE EXPRESSION; GENES, MHC CLASS II; HELA CELLS; HLA-D ANTIGENS; HUMANS; INTERFERON-GAMMA, RECOMBINANT; KINETICS; MOLECULAR SEQUENCE DATA; MUTAGENESIS, SITE-DIRECTED; NUCLEAR PROTEINS; PROTEIN ISOFORMS; RECOMBINANT PROTEINS; RNA, MESSENGER; TRANS-ACTIVATORS; TRANSFECTION; TUMOR CELLS, CULTURED;

EID: 0035993979     PISSN: 09538178     EISSN: None     Source Type: Journal    
DOI: 10.1093/intimm/dxf060     Document Type: Article

References (51)

1. MHC-dependent antigen processing and peptide presentation: Providing ligands for T lymphocyte activation
2. Sequences and factors: A guide to MHC class II transcription
3. Conserved major histocompatibility complex class II boxes X and Y are transcriptional control elements and specifically bind nuclear proteins
4. A novel DNA-binding regulatory factor is mutated in primary MHC class II deficiency (bare lymphocyte syndrome)
5. A gene encoding a novel RFX-associated transactivator is mutated in the majority of MHC class II deficiency patients
6. RFXAP, a novel subunit of the RFX DNA binding complex is mutated in MHC class II deficiency
7. Purified X2 binding protein (X2BP) cooperatively binds the class II MHC X box region in the presence of purified RFX, the X box factor deficient in the bare lymphocyte syndrome
8. A multiplicity of CCAAT box-binding proteins
9. Transcriptional scaffold: CIITA interacts with NF-Y, RFX, and CREB To cause stereospecific regulation of the class II major histocompatibility complex promoter
10. Activation of class II MHC genes requires both the X box region and the class II transactivator (CIITA)
11. The class II transactivator CIITA interacts with the TBP-associated factor TAFII32
12. Involvement of CREB binding protein in expression of major histocompatibility complex class II genes via interaction with the class II transactivator
13. Importance of acidic, proline/serine/threonine-rich, and GTP-binding regions in the major histocompatibility complex class II transactivator: Generation of transdominant-negative mutants
14. A defect in the nuclear translocation of CIITA causes a form of type II bare lymphocyte syndrome
15. Mechanisms of nuclear import and export that control the subcellular localization of class ii transactivator
16. Acetylation by PCAF enhances CIITA nuclear accumulation and transactivation of major histocompatibility complex class II genes
17. CIITA leucine-rich repeats control nuclear localization, in vivo recruitment to the major histocompatibility complex (MHC) class II enhanceosome, and MHC class II gene transactivation
18. Two distinct domains within CIITA mediate self-association: Involvement of the GTP-binding and leucine-rich repeat domains
19. Self-association of CIITA and its transactivation potential
20. Self-association of class ii transactivator correlates with its intracellular localization and transactivation
21. Complementation cloning of an MHC class II transactivator mutated in hereditary MHC class II deficiency (or bare lymphocyte syndrome)
22. Maturation of dendritic cells is accompanied by rapid transcriptional silencing of class II transactivator (CIITA) expression
23. Regulation of MHC class II expression by interferon-gamma mediated by the transactivator gene CIITA
24. Quantitative control of MHC class II expression by the transactivator CIITA
25. Isolation of a B-cell-specific promoter for the human class II transactivator
26. Expression of MHC class II molecules in different cellular and functional compartments is controlled by differential usage of multiple promoters of the transactivator CIITA
27. Two distinct gamma interferon-inducible promoters of the major histocompatibility complex class II transactivator gene are differentially regulated by STAT1, interferon regulatory factor 1, and transforming growth factor beta
28. A novel role for the major histocompatibility complex class II transactivator CIITA in the repression of IL-4 production
29. MHC class II transactivator inhibits IL-4 gene transcription by competing with NF-AT to bind the coactivator CREB binding protein (CBP)/p300
30. The class II transactivator prevents activation-induced cell death by inhibiting Fas ligand gene expression
31. A 36-amino-acid region of CIITA is an effective Inhibitor of CBP: Novel mechanism of gamma interferon-mediated suppression of collagen alpha(2)(I) and other promoters
32. The RAG cell line defines a new complementation group of MHC class II deficiency
33. Evidence for retinoblastoma protein (RB) dependent and independent IFN-γ responses: RB coordinately rescues IFN-γ induction of MHC class II gene transcription in noninducible breast carcinoma cells
34. Constitutive expression of MHC class II genes in melanoma cell lines results from the transcription of class II transactivator abnormally initiated from its B cell-specific promoter
35. MHC class-II deficient tumor cell lines with a defective expression of the class II transactivator (CIITA)
36. Detection of a novel human class II HLA antigen
37. A novel HLA-D/DR-like antigen specific for human B lymphoid cells. Biochemical evidence for similarity to but nonidentity with known HLA-D/DR antigens
38. Class II transactivator (CIITA) is sufficient for the inducible expression of major histocompatibility complex class II genes
39. Combined immunodeficiency with defective expression of HLA antigens: Modulation of an abnormal HLA and functional studies
40. CIITA coordinates multiple histone acetylation modifications at the HLA-DRA promoter
41. Differences in the expression and release of DR, BR, and DQ molecules in human cells treated with recombinant interferon gamma: Comparison to other interferons
42. HLA DR, DQ, and DP antigen expression in rheumatoid synovial cells: A biochemical and quantitative study
43. Response of glioma cells to interferon-gamma: Increase in class II RNA, protein and mixed lymphocyte reaction-stimulating ability
44. Molecular analysis of G1B and G3A IFN- gamma mutants reveals that defects in CIITA or RFX result in defective class II MHC and li gene induction
45. CIITA-induced occupation of MHC class II promoters is independent of the cooperative stabilization of the promoter-bound multi-protein complexes
46. Cooperative binding between factors RFX and X2bp to the X and X2 boxes of MHC class II promoters
47. Downregulation of CIITA function by protein kinase a (PKA)-mediated phosphorylation: Mechanism of prostaglandin E, cyclic AMP, and PKA inhibition of class II major histocompatibility complex expression in monocytic lines
48. Identification of distinct regions of 5′ flanking DNA that mediate constitutive, IFN-gamma, STAT1, and TGF-beta-regulated expression of the class II transactivator gene
49. Dendritic cell-specific MHC class II transactivator contains a caspase recruitment domain that confers potent transactivation activity
50. The histone acetyltransferase domains of CBP and pCAF are not necessary for cooperativity with CIITA
51. DNA content and MHC class II antigen expression in malignant melanoma: Clinical course